Stephen Kraus is a Partner at Bessemer Venture Partners and leads the firm’s health care investing activities.
He currently sits on the Boards of Bright Health, Artemis Health, Groups, Qventus, Welltok, Alcresta, TScan, and is a Board Observer at Collective Medical Technologies.
Steve led Bessemer’s successful investments in Liazon, acquired by Towers Watson; Ovascience, Sirtris Pharmaceuticals; Affymax; Aveo; Alnara, acquired by Eli Lilly; Transave; Stromedix, acquired by Biogen Idec, Verastem, Acceleron, Restore Medical, acquired by Medtronic, and Flex Pharma.
Steve has been recognized by Forbes Magazine and Rock Health as one of the top health care investors in the industry.
Prior to joining Bessemer, Steve worked for a growth-stage, private-equity firm and as a management consultant at Bain & Company. He has also worked on several different political campaigns throughout his career.
He serves as an Observer at Beth Israel Deaconess Medical Center, an advisor to Boston Children’s Hospital and the Harvard Business School’s Center for Entrepreneurship, and on the investment committees of BCBS Massachusetts.
Steve is co-host of “A Healthy Dose” podcast and often blogs about his views on the health care industry.